Abstract
The food-grade bacterium Lactococcus lactis has been extensively investigated during the last two decades as a delivery vector for therapeutic proteins, DNA and vaccine antigens. The bacterium represents a safe, genetically tractable vector capable of producing heterologous therapeutic proteins at mucosal sites. Here we review recent work in which re- combinant L. lactis strains have been exploited as agents to treat inflammatory bowel disease, allergy and cancer. We also describe the ability of L. lactis to deliver proteins with adjuvant potential, vaccines and DNA and discuss the therapeutic possibilities of this approach.
| Original language | English |
|---|---|
| Pages (from-to) | 34-45 |
| Number of pages | 12 |
| Journal | Current Gene Therapy |
| Volume | 10 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Feb 2010 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Delivery
- IBD
- Immunomodulation
- Lactococcus
- Therapeutic protein
- Vaccine
- Vector
Fingerprint
Dive into the research topics of 'Lactococcus lactis as a cell factory for delivery of therapeutic proteins'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver